CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics AG shares surged in early afternoon U.S. trade Thursday, up 11.7% at $58.15. Investors moved into gene-editing stocks. The Nasdaq name hit an intraday high of $59.00. About 2.0 million shares traded, putting its market cap close to $5.6 billion.

Biotechnology · NASDAQ:BEAM · NASDAQ:CRSP · NASDAQ:EDIT · NASDAQ:NTLA · NASDAQ:VRTX · NYSE:LLY · Stock Market
Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics shares rose about 5% to $28.24 by early afternoon on Tuesday after Bank of America raised its price target to $45 from $43 and kept a buy rating, according to a note carried by Futu News. The stock opened at $26.64, hit a session high of $30.49 and traded about 1.1 million shares. Futunn News
6 January 2026
Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

ARK’s Wednesday trade disclosure shows the firm bought 521,867 shares of Pinterest across three funds after the visual discovery platform cratered on guidance. The add looks like a classic Cathie Wood “buy the dip” move: step into high‑conviction names when volatility runs hottest. Investing.com+1
6 November 2025
········
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics globenewswire.com. – Price: ~$30 per share ts2.tech. – Sector: Biotechnology globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy and Orphan Drug designations to Beam’s lead programs globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside.
21 October 2025
··
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the dayfinviz.com. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart – the stock’s 50-day moving average recently rose above its 200-day averagefinviz.com, a technical signal often seen as confirmation of a positive trend reversal. Zacks noted that BEAM had rallied ~6.8% over the prior four weeks leading into this golden-cross eventfinviz.com, helping shift its Zacks Rank to #2. The sharp Monday jump may have been fueled by momentum traders reacting to these technicals and upbeat analyst commentary, as well as broader sector tailwinds.
20 October 2025
·····
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.